23-Valent Pneumococcal Polysaccharide Vaccine Market (Updated Version Available)

The report offers detailed coverage of 23-Valent Pneumococcal Polysaccharide Vaccine industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading 23-Valent Pneumococcal Polysaccharide Vaccine by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
North America is the largest supplier and consumption market of 23-Valent Pneumococcal Polysaccharide Vaccine, with a production market share nearly 70% and sales market share nearly 28% in 2015. Because Sanofipasteur, a competitor from Europe, transferred its vaccine type gradually, the production market share of North America in the world has enjoyed a dramatic increase.
The second place is EU, following North America with production market share of 15% and sales market share nearly 20% in 2015.China is another important market of 23-Valent Pneumococcal Polysaccharide Vaccine, enjoying 10% production market share and 15% sales market share in 2015.

The report forecast global 23-Valent Pneumococcal Polysaccharide Vaccine market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2025.

First, this report covers the present status and the future prospects of the global 23-Valent Pneumococcal Polysaccharide Vaccine market for 2015-2025.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

Key Companies
MSD
Sanofipasteur
CDIBP

At the same time, we classify 23-Valent Pneumococcal Polysaccharide Vaccine according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Market Segment as follows:
Market by Order Type
Single Dose Vial
Pre-filled Syringe
Market by Application
For Children (2-10)
For Person (10-64)
For The Old (≥65)

By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the 23-Valent Pneumococcal Polysaccharide Vaccine market for the forecast period 2021 - 2025?
• What are the driving forces in the 23-Valent Pneumococcal Polysaccharide Vaccine market for the forecast period 2021 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the 23-Valent Pneumococcal Polysaccharide Vaccine industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?